Compounds > 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin
Page last updated: 2024-12-11

5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9810111
SCHEMBL ID498511
MeSH IDM0371161

Synonyms (16)

Synonym
sqn 400
unii-28g2rw9qu8
5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin
aqn400
28g2rw9qu8 ,
122341-39-3
m-thpbc
mthpbc
phenol, 3,3',3'',3'''-(7,8,17,18-tetrahydro-21h,23h-porphine-5,10,15,20-tetrayl)tetrakis-
SCHEMBL498511
3-[10,15,20-tris(3-hydroxyphenyl)-2,3,12,13,22,24-hexahydroporphyrin-5-yl]phenol
sqn-400
3,3',3'',3'''-(7,8,17,18-tetrahydro-21h,23h-porphine-5,10,15,20-tetrayl)tetrakis(phenol)
sqn400
3-((1z,5z,9z,14z)-10,15,20-tris(3-hydroxyphenyl)-2,3,12,13,22,24-hexahydroporphyrin-5-yl)phenol
DTXSID401224451

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A rat liver model of photodynamic tissue necrosis was used to determine the in vivo action spectrum and the dose-response relationships of tissue destruction with drug and light doses."( In vivo photodynamic characteristics of the near-infrared photosensitizer 5,10,15,20-tetrakis(M-hydroxyphenyl) bacteriochlorin.
de Jode, ML; Grahn, MF; Rezzoug, H; Rovers, JP, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
temoporfin
temoporfin: used as PHOTOCHEMOTHERAPY		210
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.0210L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Liver
[description not available]		04.6632
Colorectal Cancer
[description not available]		04.3722
Liver Neoplasms
Tumors or cancer of the LIVER.		04.6632
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		03.821
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		04.3722
Disease Exacerbation
[description not available]		02.0210
Cancer of Colon
[description not available]		02.4220
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0210
Metastase
[description not available]		02.0210
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4220
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0210